Search 

The Pershing Square Sohn Cancer Research Alliance is dedicated to playing a catalytic role in accelerating cures for cancer by enabling the pursuit of the most innovative and advanced cancer research and by facilitating collaborations between science and business.

The Alliance will launch a series of initiatives to further its Mission.

Karen and Bill Ackman established The Pershing Square Foundation in December 2006. Bill is the CEO and Portfolio Manager of Pershing Square Capital Management, L.P. Based in New York, The Pershing Square Foundation has committed close to $350 million in grants and social investments to support exceptional leaders and innovative organizations that tackle important social issues and deliver scalable and sustainable impact across the globe.

The Foundation’s commitment to be a philanthropic catalyst inspired Bill Ackman to partner with The Sohn Conference Foundation to accelerate cures for cancer. The Sohn Conference Foundation was born from the loss of Ira Sohn, a Wall Street professional who succumbed to cancer at 29. In 1995, his colleagues, friends, and family joined forces to honor his memory. The Sohn Conference Foundation is dedicated to supporting innovative initiatives to cure and treat pediatric cancer. Identifying specific areas of need, the Foundation funds groundbreaking research, state-of-the-art technology, and programs to target cures and improve patient care.

The alliance of these two foundations will leverage their respective resources, their investigators, and their opportunities to exponentially impact the field of cancer research.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Novel target discovery. 
•Biotherapeutic (Immunotherapy & ADC) early discovery.
•Biotherapeutic (Immunotherapy & ADC) design and development.
•Intrapreneurship.
•Duties with Pfizer External R&D Innovation & Scouting for novel technologies in therapeutics, diagnostics & medical devices: 
(Screen & evaluate early/mid stage (inter)national biotech/pharma technologies that 
align with Pfizer’s R&D interest/vision & aid with triaging and funding of such technologies toward
corporate strategic partnerships). 
•NYC Bio-entrepreneurship mentor for early stage life science ventures through Pfizer Business 
Development and the New York Economic Development Council (ELabNYC, British Consulate, Columbia University).
•Adjunct Faculty member for National Science Foundation (NSF) I-Corps: 
The NYC Regional Innovation Node (NYCRIN): Bioentrepreneurship ventures.

A clinical research provider that conducts clinical research for pharmaceutical and biotechnological companies as well as government sponsored trials. We also facilitate training programs for clinical research practitioners and site preparation for studies.

We also aim to help clinical research facilities and professionals conduct clinical trials following GCP/ICH. By doing so we believe will be beneficial to pharmaceutical companies as it would allow for clinical trials to run smoother and more efficiently. It will also help subjects get quality service during the clinical studies.

Donec sodales a quam in imperdiet. Aliquam massa libero, malesuada nec interdum sit amet, gravida quis nibh. Praesent facilisis tristique egestas. Curabitur vitae metus vitae libero iaculis suscipit. Nullam non velit metus. Curabitur at euismod felis. Aenean viverra sem sit amet ante bibendum, sit amet vehicula eros dapibus.

We build financial products so you can participate in the healthcare and life science economy. Companies, investors, consumers and entrepreneurs will have access to financial products to create and/or manage their financial exposure to healthcare and the life science sector.

Poliwogg's management team has extensive experience in finance, healthcare, foundations, government and investing. It combines that expertise with a passion for increasing and broadening investment in healthcare, the largest sector of the American economy.

At Precision for Medicine, we specialize in accelerating the development, approval and launch of complex or first-in-class medical technologies.  We work regularly with medical device, diagnostics and life sciences companies as well as with investors in this space.  We have expert teams in each of regulatory affairs, biostatistics and analytics, clinical trial services, commercial strategy and market access/reimbursement.  Our experts work within and across these verticals to develop the latest techniques for product success.  

Core services include:

To-Market Strategy, a collaborative effort to manage risk and maximize opportunity at each stage of product development 

Due Diligence and Opportunity Assessments, to inform potential investments or new areas of product development

Regulatory Strategy and Support, including U.S. FDA, E.U. and global regulatory stratgies, negotitations and submissions

Evidence Development Strategy, including advanced non-clinical and clinical trial designs, statistical analysis plans, and literature-based approaches

Clinical Trial Services, from study start through conclusion and reporting

KOL Recruitment and management of key clinical advisors (CABs, SABs, KOLs, expert panels and reports, study investigators, etc.)

Market Access Services, including payer communications, reimbursement strategy, and health economics

Personalized Medicine Strategies, including responder analyses, companion diagnostics and biomarker identification 

Digital Medicine Strategy, including software-based products and accessory apps

Business Strategy, including business model ideation, market research, due diligence and fundraising support

oronary Artery Disease (CAD) is the leading cause of death worldwide, accounting for over 7 Million deaths annually — more than any other disease category.

Premier Heart's Multifunction Cardiogram is the only non-invasive online diagnostic testing tool designed to assist physicians in quickly and accurately detecting heart diseases, including CAD ischemia.
When compared to traditional methods MCG has consistently been able to more accurately detect ischemia at earlier stages, enabling physicians to intervene and save lives.

The results from MCG have been validated in double-blind clinical studies where our system has demonstrated accuracy comparable to coronary angiography (90% overall sensitivity, 85% specificity).
This level of accuracy results from advanced techniques in signal processing and systems analysis combined with our unmatched clinical database which allows MCG to provide quantitative, evidence-based results to assist in reaching a diagnosis.

We invite you to review our clinical trial results, user endorsements and technical data. If you want to learn more about using MCG in your practice or would like more information about our technology please feel free to contact us.